Tricuspid annuloplasty in ischemic cardiomyopathy patients undergoing restrictive mitral annuloplasty

BackgroundWe elucidated the impact of concomitant tricuspid annuloplasty (TAP) on postoperative tricuspid regurgitation (TR), pulmonary hypertension (PH) and survival in patients with ischemic cardiomyopathy undergoing restrictive mitral annuloplasty (RMA).MethodsThis study included 234 patients wit...

Full description

Saved in:
Bibliographic Details
Main Authors: Yusuke Misumi, Satoshi Kainuma, Daisuke Yoshioka, Takuji Kawamura, Ai Kawamura, Shin Yajima, Shunsuke Saito, Takashi Yamauchi, Masaki Taira, Kazuo Shimamura, Shigeru Miyagawa
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2025.1542619/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849727611114094592
author Yusuke Misumi
Satoshi Kainuma
Daisuke Yoshioka
Takuji Kawamura
Ai Kawamura
Shin Yajima
Shunsuke Saito
Takashi Yamauchi
Masaki Taira
Kazuo Shimamura
Shigeru Miyagawa
author_facet Yusuke Misumi
Satoshi Kainuma
Daisuke Yoshioka
Takuji Kawamura
Ai Kawamura
Shin Yajima
Shunsuke Saito
Takashi Yamauchi
Masaki Taira
Kazuo Shimamura
Shigeru Miyagawa
author_sort Yusuke Misumi
collection DOAJ
description BackgroundWe elucidated the impact of concomitant tricuspid annuloplasty (TAP) on postoperative tricuspid regurgitation (TR), pulmonary hypertension (PH) and survival in patients with ischemic cardiomyopathy undergoing restrictive mitral annuloplasty (RMA).MethodsThis study included 234 patients with ischemic cardiomyopathy (LV ejection fraction ≤40%) who underwent RMA. Of them, 114 (49%) underwent concomitant TAP for secondary TR. The primary endpoint was freedom from significant recurrence (i.e., moderate or greater) and progression (≥2+ grades) in TR. The secondary endpoints were postoperative pulmonary artery systolic pressure (sPAP) and overall survival.ResultsThe 30-day mortality was not different (0.9% vs. 0.8%, P = 0.97), despite higher EuroSCORE II score (median, 9.3% vs. 7.2%, P = 0.016) for TAP group. At baseline, TAP group had higher TR grades (2.4 ± 0.8 vs. 1.4 ± 0.6, P < 0.001) and sPAP (51 ± 16 vs. 44 ± 12 mmHg, P < 0.001). At 5-year post-surgery, RMA with TAP demonstrated higher freedom from recurrence or progression of TR (91 ± 3% vs. 81 ± 4%, log-rank P = 0.036), yielding nearly identical sPAP (42 ± 18 vs. 40 ± 16 mmHg, P = 0.54). Multivariable analysis demonstrated concomitant TAP was independently associated with freedom from significant recurrence in TR. Overall survival were not different between the groups (P = 0.74).ConclusionsIn patients with ischemic cardiomyopathy, concomitant TAP did not increase operative mortality and better reduced TR, resulting in comparable PH severity and long-term survival, compared to RMA alone.
format Article
id doaj-art-4a9f39c1c6de4b51bdea7d1c37c238f9
institution DOAJ
issn 2297-055X
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cardiovascular Medicine
spelling doaj-art-4a9f39c1c6de4b51bdea7d1c37c238f92025-08-20T03:09:48ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-05-011210.3389/fcvm.2025.15426191542619Tricuspid annuloplasty in ischemic cardiomyopathy patients undergoing restrictive mitral annuloplastyYusuke MisumiSatoshi KainumaDaisuke YoshiokaTakuji KawamuraAi KawamuraShin YajimaShunsuke SaitoTakashi YamauchiMasaki TairaKazuo ShimamuraShigeru MiyagawaBackgroundWe elucidated the impact of concomitant tricuspid annuloplasty (TAP) on postoperative tricuspid regurgitation (TR), pulmonary hypertension (PH) and survival in patients with ischemic cardiomyopathy undergoing restrictive mitral annuloplasty (RMA).MethodsThis study included 234 patients with ischemic cardiomyopathy (LV ejection fraction ≤40%) who underwent RMA. Of them, 114 (49%) underwent concomitant TAP for secondary TR. The primary endpoint was freedom from significant recurrence (i.e., moderate or greater) and progression (≥2+ grades) in TR. The secondary endpoints were postoperative pulmonary artery systolic pressure (sPAP) and overall survival.ResultsThe 30-day mortality was not different (0.9% vs. 0.8%, P = 0.97), despite higher EuroSCORE II score (median, 9.3% vs. 7.2%, P = 0.016) for TAP group. At baseline, TAP group had higher TR grades (2.4 ± 0.8 vs. 1.4 ± 0.6, P < 0.001) and sPAP (51 ± 16 vs. 44 ± 12 mmHg, P < 0.001). At 5-year post-surgery, RMA with TAP demonstrated higher freedom from recurrence or progression of TR (91 ± 3% vs. 81 ± 4%, log-rank P = 0.036), yielding nearly identical sPAP (42 ± 18 vs. 40 ± 16 mmHg, P = 0.54). Multivariable analysis demonstrated concomitant TAP was independently associated with freedom from significant recurrence in TR. Overall survival were not different between the groups (P = 0.74).ConclusionsIn patients with ischemic cardiomyopathy, concomitant TAP did not increase operative mortality and better reduced TR, resulting in comparable PH severity and long-term survival, compared to RMA alone.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1542619/fullischemic cardiomyopathyrestrictive mitral annuloplastytricuspid annuloplastyfunctional mitral regurgitationtricuspid regurgitation
spellingShingle Yusuke Misumi
Satoshi Kainuma
Daisuke Yoshioka
Takuji Kawamura
Ai Kawamura
Shin Yajima
Shunsuke Saito
Takashi Yamauchi
Masaki Taira
Kazuo Shimamura
Shigeru Miyagawa
Tricuspid annuloplasty in ischemic cardiomyopathy patients undergoing restrictive mitral annuloplasty
Frontiers in Cardiovascular Medicine
ischemic cardiomyopathy
restrictive mitral annuloplasty
tricuspid annuloplasty
functional mitral regurgitation
tricuspid regurgitation
title Tricuspid annuloplasty in ischemic cardiomyopathy patients undergoing restrictive mitral annuloplasty
title_full Tricuspid annuloplasty in ischemic cardiomyopathy patients undergoing restrictive mitral annuloplasty
title_fullStr Tricuspid annuloplasty in ischemic cardiomyopathy patients undergoing restrictive mitral annuloplasty
title_full_unstemmed Tricuspid annuloplasty in ischemic cardiomyopathy patients undergoing restrictive mitral annuloplasty
title_short Tricuspid annuloplasty in ischemic cardiomyopathy patients undergoing restrictive mitral annuloplasty
title_sort tricuspid annuloplasty in ischemic cardiomyopathy patients undergoing restrictive mitral annuloplasty
topic ischemic cardiomyopathy
restrictive mitral annuloplasty
tricuspid annuloplasty
functional mitral regurgitation
tricuspid regurgitation
url https://www.frontiersin.org/articles/10.3389/fcvm.2025.1542619/full
work_keys_str_mv AT yusukemisumi tricuspidannuloplastyinischemiccardiomyopathypatientsundergoingrestrictivemitralannuloplasty
AT satoshikainuma tricuspidannuloplastyinischemiccardiomyopathypatientsundergoingrestrictivemitralannuloplasty
AT daisukeyoshioka tricuspidannuloplastyinischemiccardiomyopathypatientsundergoingrestrictivemitralannuloplasty
AT takujikawamura tricuspidannuloplastyinischemiccardiomyopathypatientsundergoingrestrictivemitralannuloplasty
AT aikawamura tricuspidannuloplastyinischemiccardiomyopathypatientsundergoingrestrictivemitralannuloplasty
AT shinyajima tricuspidannuloplastyinischemiccardiomyopathypatientsundergoingrestrictivemitralannuloplasty
AT shunsukesaito tricuspidannuloplastyinischemiccardiomyopathypatientsundergoingrestrictivemitralannuloplasty
AT takashiyamauchi tricuspidannuloplastyinischemiccardiomyopathypatientsundergoingrestrictivemitralannuloplasty
AT masakitaira tricuspidannuloplastyinischemiccardiomyopathypatientsundergoingrestrictivemitralannuloplasty
AT kazuoshimamura tricuspidannuloplastyinischemiccardiomyopathypatientsundergoingrestrictivemitralannuloplasty
AT shigerumiyagawa tricuspidannuloplastyinischemiccardiomyopathypatientsundergoingrestrictivemitralannuloplasty